Merck Total Current Liabilities 2010-2024 | MRK

Merck total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
  • Merck total current liabilities for the quarter ending September 30, 2024 were $29.586B, a 28.11% increase year-over-year.
  • Merck total current liabilities for 2023 were $25.694B, a 6% increase from 2022.
  • Merck total current liabilities for 2022 were $24.239B, a 1.54% increase from 2021.
  • Merck total current liabilities for 2021 were $23.872B, a 12.64% decline from 2020.
Merck Annual Total Current Liabilities
(Millions of US $)
2023 $25,694
2022 $24,239
2021 $23,872
2020 $27,327
2019 $22,220
2018 $22,206
2017 $18,614
2016 $17,204
2015 $19,201
2014 $18,397
2013 $17,868
2012 $18,348
2011 $16,245
2010 $15,641
2009 $15,641
Merck Quarterly Total Current Liabilities
(Millions of US $)
2024-09-30 $29,586
2024-06-30 $26,060
2024-03-31 $25,099
2023-12-31 $25,694
2023-09-30 $23,094
2023-06-30 $23,394
2023-03-31 $23,131
2022-12-31 $24,239
2022-09-30 $22,998
2022-06-30 $23,168
2022-03-31 $22,316
2021-12-31 $23,872
2021-09-30 $23,728
2021-06-30 $21,906
2021-03-31 $26,361
2020-12-31 $27,327
2020-09-30 $20,405
2020-06-30 $22,178
2020-03-31 $23,483
2019-12-31 $22,220
2019-09-30 $20,684
2019-06-30 $20,085
2019-03-31 $18,543
2018-12-31 $22,206
2018-09-30 $18,586
2018-06-30 $18,128
2018-03-31 $16,960
2017-12-31 $18,614
2017-09-30 $19,467
2017-06-30 $18,758
2017-03-31 $19,823
2016-12-31 $17,204
2016-09-30 $15,555
2016-06-30 $14,918
2016-03-31 $17,568
2015-12-31 $19,201
2015-09-30 $17,583
2015-06-30 $17,508
2015-03-31 $20,442
2014-12-31 $18,397
2014-09-30 $25,927
2014-06-30 $17,928
2014-03-31 $22,470
2013-12-31 $17,868
2013-09-30 $18,215
2013-06-30 $18,402
2013-03-31 $18,802
2012-12-31 $18,348
2012-09-30 $15,583
2012-06-30 $16,912
2012-03-31 $16,582
2011-12-31 $16,245
2011-09-30 $16,593
2011-06-30 $15,763
2011-03-31 $15,662
2010-12-31 $15,641
2010-09-30 $17,323
2010-06-30 $15,421
2010-03-31 $16,455
2009-12-31 $15,641
2009-09-30 $8,026
2009-06-30 $11,507
2009-03-31 $13,416
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $244.211B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94